-
公开(公告)号：KR101346181B1
公开(公告)日：2014-01-03
申请号：KR1020130016907
申请日：2013-02-18
Applicant: 강원대학교산학협력단
Abstract: The present invention relates to an anti-MIC-1 monoclonal antibody inhibiting the induction of angiogenesis by MIC-1 and, more particularly, to an antibody specifically binding to MIC-1 comprising: light chain variable regions in which complementarity determining regions, CDR1, CDR2, and CDR3 have amino acid sequences for sequence number 1, 2, and 3 respectively; and heavy chain variable regions in which complementarity determining regions, CDR1, CDR2, and CDR3 have amino acid sequences for sequence number 4, 5, and 6 respectively. The antibody in the present invention effectively inhibits angiogenesis induced by MIC-1, thereby blocking tumor growth and metastasis. And the treatment for disorders related to hyper angiogenesis, which have been increasing in number recently, such as arthritis, diabetes, retina diseases, atherosclerosis, and psoriasis, etc. as well as cancers can be expected. The effectiveness is considered because the antibody in the present invention specifically binds to MIC-1 and interrupts the binding between MIC-1 and receptor thereof. Also, the development of more effective antibody can be expected by modifying the information about the antibody in the present invention.
Abstract translation: 本发明涉及通过MIC-1抑制血管生成诱导的抗MIC-1单克隆抗体，更具体地，涉及与MIC-1特异性结合的抗体，所述抗体包含：轻链可变区，其中互补决定区CDR1， CDR2和CDR3分别具有序列号1,2和3的氨基酸序列; 和重链可变区，其中互补决定区CDR1，CDR2和CDR3分别具有序列号4,5和6的氨基酸序列。 本发明中的抗体有效抑制由MIC-1诱导的血管发生，从而阻断肿瘤的生长和转移。 并且预期近年来一直在增加的关于高血管发生的疾病如关节炎，糖尿病，视网膜疾病，动脉粥样硬化和牛皮癣等以及癌症的治疗。 考虑到本发明的抗体与MIC-1特异性结合并中断MIC-1与其受体之间的结合，因此考虑到有效性。 此外，通过修改本发明中关于抗体的信息，可以预期开发更有效的抗体。
-
公开(公告)号：KR1020110095611A
公开(公告)日：2011-08-25
申请号：KR1020100015177
申请日：2010-02-19
Applicant: 강원대학교산학협력단
CPC classification number: A61K38/1841
Abstract: PURPOSE: A pharmaceutical composition containing MIC-1 gene or expression protein thereof is provided to be used for wound healing as a therapeutic agent. CONSTITUTION: A pharmaceutical composition for wound healing contains MIC-1(macrophage inhibitory cytokine-1) gene or expression protein thereof as an active ingredient. The MIC-1 gene encodes an amino acid of sequence number 2 or 7. The MIC-1 gene is inserted to a recombinant vector. The MIC-1 protein has an amino acid sequence of sequence number 2 or 7. The MIC-1 protein is expressed from the expression vector.
Abstract translation: 目的：提供含有MIC-1基因或其表达蛋白质的药物组合物作为治疗剂用于伤口愈合。 构成：用于伤口愈合的药物组合物含有MIC-1（巨噬细胞抑制性细胞因子-1）基因或其表达蛋白作为活性成分。 MIC-1基因编码序列号为2或7的氨基酸。将MIC-1基因插入重组载体。 MIC-1蛋白具有序列号2或7的氨基酸序列。表达载体表达MIC-1蛋白。
-
公开(公告)号：KR101177375B1
公开(公告)日：2012-08-27
申请号：KR1020100015177
申请日：2010-02-19
Applicant: 강원대학교산학협력단
CPC classification number: A61K38/1841
Abstract: 본 발명은 MIC-1을 함유하는 상처 치료용 약학적 조성물에 관한 것으로, 더욱 구체적으로 MIC-1(macrophage inhibitory cytokine-1) 유전자 또는 그의 발현 단백질을 유효성분으로 함유하는 상처 치료용 약학적 조성물에 관한 것이다. 본 발명에 따르면, MIC-1은 VEGF와 유사하게 저산소 조건에서 발현이 유도되고 상처치료에 효과를 나타내나, VEGF와 달리 염증반응을 촉발하지 않고 혈관누수를 유도하지 않기 때문에, 급성 또는 만성 상처치료를 위한 유전자 치료제 및 피부외용제로서 사용될 수 있다.
-
公开(公告)号：KR101346132B1
公开(公告)日：2013-12-31
申请号：KR1020130016915
申请日：2013-02-18
Applicant: 강원대학교산학협력단
IPC: C07K16/24 , C12N15/13 , A61K39/395 , A61P35/00
Abstract: The present invention relates to an anti-MIC-1 monoclonal antibody, MBM-14 inhibiting angiogenesis of MIC-1, and more specifically, to an antibody which specifically combines to MIC-1 containing a light chain variable region with amino acid sequences 1,2 and 3 on complementarity determining regions which are CDR1, CDR2 and CDR3 and heavy chain variable region with amino acid sequences 4,5 and 6 on complementarity determining regions which are CDR1, CDR2 and CDR3. The antibody of the present invention is capable of effectively suppressing angiogenesis induced by MIC-1. Therefore, growth and metastasis of tumors can be stopped, and by using the present invention, treatments can be possible not only cancer, but also diseases related to angiogenesis such as arthritis, diabetes, retina disease, arteriosclerosis and psoriasis. Such treatments can be possible since the antibody of the present invention specifically combines to MIC-1 to disturb combination between MIC-1 and a receptor. In addition, antibodies with improved treatments effects can be invented based on the information of the antibody of the present invention.
Abstract translation: 本发明涉及抗MIC-1单克隆抗体，MBM-14抑制MIC-1的血管生成，更具体地说，涉及与含有轻链可变区的MIC-1与氨基酸序列1， 2和3对互补决定区是CDR1，CDR2和CDR3，重链可变区与氨基酸序列4,5和6互补决定区是CDR1，CDR2和CDR3。 本发明的抗体能够有效抑制由MIC-1引起的血管生成。 因此，可以停止肿瘤的生长和转移，并且通过使用本发明，不仅可以进行癌症治疗，还可以进行与血管生成相关的疾病如关节炎，糖尿病，视网膜疾病，动脉硬化和牛皮癣的治疗。 这样的处理是可能的，因为本发明的抗体与MIC-1特异性结合以干扰MIC-1和受体之间的组合。 此外，可以基于本发明的抗体的信息来发明具有改善的治疗效果的抗体。
-
-
-
Search Results
4
records
(took 0.035 seconds)
